Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice

Frazier-Mironer, A., Dougados, M., Mariette, X., Cantagrel, A., Deschamps, V., Flipo, R. M., … Combe, B. (2014). Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Revue Du Rhumatisme (Edition Francaise), 81(6), 483–490. https://doi.org/10.1016/j.rhum.2014.07.001